Biogen Licenses Immune Drug from Vanqua Bio
Biogen has licensed a preclinical drug from Vanqua Bio, designed to inhibit "C5aR1", a part of the immune system that regulates inflammation.
The deal includes an upfront payment of $70 million for exclusive, worldwide rights to the drug, with potential additional payments of up to $990 million depending on development, regulatory, and commercial milestones.
- Biogen will lead all future development, manufacturing, and commercialization efforts.
- Vanqua Bio may also receive tiered royalties on net sales if the drug comes to market.
The drug is designed to inhibit a protein that helps control inflammation as well as the immune system’s response to pathogens and harmful cells.
Author's summary: Biogen invests over $1 billion in immune drug.
More News
- OBITUARY: Nancy Yvonne Detrick, 1951-2025
- Ipswich Town must rue their summer turnover as former stars thrive in the Championship: Opinion News: The72 - Football League News
- Veteran actor Satish Shah passes away at 74
- Film & TV Comedian Satish Shah passes away aged 74
- Catherine Connolly Projected to Win Irish Presidency
- Jade Cargill Turns HEEL On SMACKDOWN In Brutal Attack On WWE Women's Champion Tiffany Stratton
- OBITUARY: Christine Ann Patton, 1950-2025
- What Variety Of Allium You Should Be Growing For The Largest Possible Blooms - House Digest
- The Erie Canal: How A ‘Big Ditch’ Transformed America’s Faith
- Satish Shah, Veteran Actor and Comedy Icon, Passes Away at 7